Status:
COMPLETED
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Advanced Solid Malignancies
Eligibility:
All Genders
25-150 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.
Detailed Description
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Soli...
Eligibility Criteria
Inclusion
- \- Japanese patients with advanced solid malignancies Over 25 years old Relatively good overall health other than cancer
Exclusion
- \- Poor bone marrow function (not producing enough blood cells). Poor liver or kidney function. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the IP or previous significant bowel resection.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01213160
Start Date
November 1 2010
End Date
June 1 2013
Last Update
June 29 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chūōku, Japan
2
Research Site
Nagoya, Japan
3
Research Site
Sapporo, Japan